Ricerca Biosciences Appoints Dr. G. Lynn Miesel as Technical Director

Ricerca Biosciences Appoints Dr. G. Lynn Miesel as Technical Director

<0> SCORR MarketingKelly Sladek, 308-237-5567 </0>

, an integrated preclinical contract research organization (CRO) providing services to the biopharmaceutical industry, announces Dr. G. Lynn Miesel as the new technical director.

In her new role, Dr. Miesel will utilize her more than 13 years of industry experience in anti-infectives to lead projects managed by Ricerca Biosciences.

Dr. Miesel’s supervisory and leadership experience in the pharmaceutical industry includes expertise in genetics, biochemistry, microbiology and infectious diseases drug discovery. She has extensive experience in project design and leadership, including international external collaborations.

“At Ricerca Biosciences, we pride ourselves in hiring talented individuals within the industry to provide our clients with unparalleled service,” stated Ricerca Biosciences Vice President of Discovery Pharmacology Jamie Baumgartner. “Dr. Miesel’s expertise will be invaluable as we continue to expand our pharmacology reach within the industry.”

Prior to her new role at Ricerca Biosciences, Dr. Miesel worked for Merck Research Laboratories as the biology collaboration lead of infectious disease research. While there, Dr. Miesel focused on project conception, design and coordination for target validation, lead identification and lead optimization programs. She successfully advanced two antibacterial lead identification programs to lead optimization and proposed and designed a lead identification program with BioRelix that led to a licensing deal. Dr. Miesel serves as an ad hoc grant reviewer for the National Institutes of Health and has coauthored sixteen peer-reviewed publications.

Ricerca Biosciences provides a full range of preclinical services from compound screening, profiling and lead optimization through full drug safety, metabolism and efficacy development support, as well as clinical supply and commercial API production capability.

, offers a comprehensive suite of discovery, preclinical and development services to support drug candidates from discovery through IND and NDA on a global scale. Capabilities include molecular through screening and profiling, -enabling toxicology, API process chemistry and cGMP manufacturing of clinical and commercial API. At Ricerca, our scientific excellence and reliable, cost-effective strategies help accelerate your drug discovery programs via our U.S.-based facilities in Concord, Ohio, and Bothell, Washington, and our ISO 9001-certified facilities in Taipei, Taiwan, and Lyon, France. The Lyon and Concord facilities hold AAALAC certification. For more information, visit .

Suggested Articles

Nearly two years after raising $75 million, iTeos Therapeutics is picking up $125 million to push its lead assets through phase 1/2 trials.

Bristol Myers Squibb and bluebird bio filed their BCMA-targeting CAR-T therapy for FDA approval, teeing it up for a potential green light in 2020.

With case counts surging and top officials infected, the U.K. is joining the testing for Gilead Sciences' much-hyped antiviral candidate remdesivir.